In early 2026, Ms. X, a rising leader in biomedical education who has asked to stay anonymous, hired our firm to secure her long-term ability to remain and work in the United States. Ms. X's academic and research record was unusually deep for someone still early in her career: as an undergraduate and post-baccalaureate researcher at a prestigious university medical center, she was first author of a Nature Communications study documenting a fatal case of amyloid-related imaging abnormalities (ARIA) in a patient treated with the Alzheimer's drug lecanemab. This study was later cited in the FDA's briefing materials for the drug's full approval and credited with directly informing the black box warning now on its label. Alongside her bench research into lysyl oxidase (LOX) and vascular pathology in Alzheimer's disease and cerebral amyloid angiopathy, she had also built and scaled the Biotech Fellowship at her company, a national nonprofit education initiative that grew to more than 1,600 fellows across 41 U.S. states and 50 countries. With her STEM OPT work authorization set to expire on July 10, 2026, Ms. X needed a durable solution in the form of a strategy to preserve both her nonimmigrant work status and her path to a green card at the same time.
The mission
The Path Law Group team quickly got to work building an O-1A petition classifying Ms. X as an individual of extraordinary ability in “biomedical innovation and its translation for diseases of aging.” A prestigious nonprofit served as the petitioner on Ms. X's behalf, supporting her continued role as Director of Education for her company, a program the aforementioned nonprofit fiscally sponsors.
The engagement was more complex than a single filing. Because Ms. X wanted to preserve her U.S. presence past her STEM OPT expiration while also pursuing permanent residency, the firm pursued the O-1A and a companion EB-2 National Interest Waiver (NIW) petition concurrently. Because of the uncertain nature of immigration policy, the decision was made for both petitions to be filed under premium processing in order to receive swift decisions. That timeline meant building two separate packages in parallel: an O-1A case demonstrating sustained national acclaim in a scientific field, and an NIW case built around the forward looking national importance of her continued work on Alzheimer's disease.
The strategy
Because Ms. X's case spanned two distinct kinds of accomplishment, laboratory science and program-building, the team built the O-1A petition around six independent evidentiary criteria, twice the three USCIS requires:
- Original contributions of major significance: We established this by anchoring her first-author Nature Communications study on fatal iatrogenic ARIA, which was cited in the FDA's lecanemab briefing document, informed the drug's black box warning, and has since been incorporated into Appropriate Use Recommendations governing how neurologists prescribe anti-amyloid therapies in the U.S. and Europe.
- A leading and critical role at her organization: We used her role at a distinguished nonprofit policy coalition, where she designed and scaled the organization's flagship Biotech Fellowship as Director of Education, to establish a leading and critical role.
- Nationally and internationally recognized awards: We included a First Place Data Blitz award at Vanderbilt's Alzheimer's Disease Research Day and her company's recognition as a Fierce 50 Social Impact Honoree to establish this criteria.
- Published material about her work in major media: We established this by including some of her work in The New York Times, the Los Angeles Times, Science, MedPage Today, and Alzforum;
- We included authorship of scholarly articles across five peer-reviewed journals.
- We included participation as a peer reviewer for Alzheimer's & Dementia: Translational Research & Clinical Interventions, judging the work of fellow researchers in her field.
A central strategic question was how to frame Ms. X's proposed field of endeavor so that it was neither so narrow that it excluded her forward-looking work in biomedical education, nor so broad that her past bench-research credentials no longer supported it. In a case check-in, Ms. X raised exactly this tension herself, asking how the firm intended to reconcile her past laboratory work with her current, non-bench role at her company. The team's answer became the throughline of both petitions: define the field around Alzheimer's disease and biomedical innovation broadly enough to encompass both halves of her career, and use her current leadership role at her company as evidence that she was well positioned to keep advancing that work. The aim was to not depart from her scientific credentials, but to position her role as a natural extension of them.
In assessing the strength of the O-1A case ahead of filing, the team flagged only one criterion where USCIS might push back: whether an early-career researcher's role could be considered “leading or critical”. It noted that Ms. X's current title as Director of Education resolved that risk directly. With that single soft spot addressed, and the remainder of the evidentiary record built across six independent criteria, the firm proceeded to file both petitions under premium processing ahead of the July 10, 2026 deadline.
Outcome
The O-1A was approved. Filed on a premium-processing timeline before Ms. X's STEM OPT work authorization expired, USCIS approved her O-1A petition, classifying her as an individual of extraordinary ability in biomedical innovation and its translation for diseases of aging. The approval allows Ms. X to continue serving as Director of Education for her company, where she leads the organization's national Biotech Fellowship program. Her companion EB-2 NIW petition continues to advance her path toward permanent residency.
